



Mithra Strengthens Management Team With Key Appointments

- **Expansion of IR and Communications functions to support the execution of Mithra's strategy**

Liège, Belgium, 4 February 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces it has strengthened its IR and Communications functions with the appointments of Ms. Alexandra Deschner as Investor Relations Officer and Ms. Maud Vanderthommen as Communications Manager.

Alexandra Deschner joins Mithra as Investor Relations Officer where she will be responsible for the investor strategy, together with the successful communication of the company's equity story to the investment community. Alexandra has nearly 20 years' combined international experience across sectors, including pharmaceutical, automotive, banking, and insurance. Alexandra joins Mithra from UCB where she held a number of roles, most recently as Director of Corporate Social Responsibility where she was responsible for the implementation and management of several new patient initiatives in Africa. Prior to this she was Director of R&D Portfolio Management and Director of Investor Relations at UCB. Alexandra holds an M.B.A. in International Management from Fordham University in New York and a Bachelor's degree in International Business from Loyola College in Maryland.

Maud Vanderthommen joins Mithra from SCK•CEN, the Belgian Nuclear Research Centre, where she acted as the Communications Manager. Maud will be responsible for the Company's internal and external communications initiatives. She has a wide experience in journalism and communications. She was previously a journalist for several media. At the Roularta Group she went on to become the Deputy Editor-in-Chief of a magazine in the medical area. Maud holds an Executive Masters Degree from the ICHEC Brussels Management School, a Master in Journalism and a Master in Roman languages, both from UCL Louvain-La-Neuve.

Francois Fornieri, CEO of Mithra Women's Health, commented: *"As part of Mithra's strategy to develop our promising pipeline of women's products, we are focused on ensuring we have the right people on board to help us deliver these objectives in 2019 and beyond. We are delighted to welcome Alexandra and Maud to the team. Their combined industry experience will play an important role in supporting the further acceleration of our strategy as we look to realise the commercial potential of our key programmes through international collaborations and partnerships in key markets."*

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Presse) : +32 473 58 61 04 – press@mithra.com

Consilium Strategic Communications

Susan Stuart, Olivia Manser, Melissa Gardiner

mithra@consilium-comms.com

+44 2 037 095 700

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important Information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com